Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Completed 4Terminated 1Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 123Breast Neoplasms 103Neoplasms 100Leukemia, Myeloid, Acute 88Melanoma 84Multiple Myeloma 81Neoplasm Metastasis 80Recurrence 68Ovarian Neoplasms 65Prostatic Neoplasms 59Lymphoma 59Colorectal Neoplasms 58Lymphoma, Non-Hodgkin 55Leukemia 55Pancreatic Neoplasms 50Lung Neoplasms 47Leukemia, Lymphocytic, Chronic, B-Cell 42Myelodysplastic Syndromes 41Carcinoma, Renal Cell 39Squamous Cell Carcinoma of Head and Neck 38Precursor Cell Lymphoblastic Leukemia-Lymphoma 38Glioblastoma 35Lymphoma, Large B-Cell, Diffuse 34Triple Negative Breast Neoplasms 33Carcinoma, Hepatocellular 33Stomach Neoplasms 29Small Cell Lung Carcinoma 27Lymphoma, Follicular 27Brain Neoplasms 26Lymphoma, Mantle-Cell 25

Interventions

sapanisertib 1pazopanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Terminated × Dermatofibrosarcoma × Clear all
NCT02601209 2022-08-23

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

National Cancer Institute (NCI)

Phase 1/2 Terminated
151 enrolled 22 charts
Sarcoma

Leiomyosarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡